NEUP•benzinga•
Neuphoria Therapeutics shares are trading higher after the company announced it achieved a $15 million milestone with its Phase 2 clinical trial launch with Merck.
Summary
No summary available.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on February 12, 2025 by benzinga